Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...

On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...

On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 821,620 shares ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

TD Cowen maintained its positive stance on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), reiterating a Buy rating and a price target of $70.00. The endorsement follows recent discussions with ...

TD Cowen maintained its positive stance on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), reiterating a Buy rating and a price target of $70.00. The endorsement follows recent discussions with the ...

Michael J. LaBarre, the Senior Vice President and Chief Technical Officer of Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ:HALO), recently executed a series of stock transactions. On October ...